A bill to increase access to pre-exposure prophylaxis to reduce the transmission of HIV.

S.3990 was introduced on March 4, 2026, by Sen. Tina Smith (D-MN) with 24 Democratic cosponsors, and referred to the Senate Committee on Health, Education, Labor, and Pensions. The bill has not advanced beyond the introductory stage, and its companion bill, HR7853, is similarly stalled in multiple House committees. The legislation would amend the Public Health Service Act and the Affordable Care Act to require private health plans to cover FDA-approved PrEP drugs and associated laboratory and monitoring services without cost-sharing, and prohibit preauthorization requirements.

There is no direct government funding in this bill — it operates through regulatory mandates on insurers, so the 'money trail' is indirect: increased prescription volume for PrEP manufacturers. The primary beneficiary is Gilead Sciences ($GILD), whose Truvada and Descovy products dominate the PrEP market. Merck ($MRK) and Johnson & Johnson ($JNJ) have HIV portfolios but are not leaders in PrEP. Insurers like UnitedHealth ($UNH) could face increased drug costs, but the mandate also reduces long-term HIV treatment costs, making the net effect uncertain.

No convergence signals were identified in the provided context. The bill is a standalone healthcare access measure with no related procurement, executive orders, or other legislative signals in the data.

Structural winners: Gilead Sciences ($GILD) — the PrEP market is directly expanded. Structural losers: none clearly identifiable at this stage, but insurers may face short-term cost pressure. The legislative path is long: committee markup, floor vote, House passage, and potential conference. With a Democratic sponsor and all cosponsors from the Democratic party, passage requires bipartisan support in a divided Congress, which is uncertain. Near-term market impact is low unless the bill gains momentum.